Have you been overwhelmed by the number of CRISPR articles published in 2017? PubMed alone has cited over 3,000 CRISPR publications in 2017! We wanted to save you from having to sieve through the databases by asking our experts to select what they thought were the most important CRISPR publications from last year.
Research conducted by Jian-Hua Luo, M.D., Ph.D. of the Pittsburgh School of Medicine is the first time gene editing has been used to specifically target cancer fusion genes, which are hybrid genes discovered in a wide array of solid tumors1.
These hybrid genes, formed from two previously separate genes, produce abnormal proteins that can be a catalyst to faster and/or further cancer growth. In patients this causes far more invasive cancers, reducing life expectancy and survival chances.
When I have read articles just like this one early on in my career, I would laugh and categorize it with blogs regarding Bigfoot and the Loch Ness Monster. However, much has changed in the past 10 years. New technologies have been developed and milestones have been reached that should have Cancer a little worried. These 3 steps might be viewed to some as obvious, but I argue that it’s how the researchers have utilized the technology wisely that has made the difference. I have identified some papers that have carved a successful path to Cancer's possible demise.
Increasingly the literature suggests that CRISPR's potential for off-target effects is not as “bad” as originally thought. Here are a few things to set your mind at ease if you’re working with the CRISPR-Cas9 system:
Laboratory-based CRISPR gene editing has only been around a short while but is already revolutionizing the way we do biological research - allowing scientists to study gene function in more robust or even previously un-imagined ways.
The adoption of CRISPR in 2015 was staggering, and keeping up with publications was a challenge. At Horizon, we polled our scientists on what their favorite CRISPR publications of 2015 were and why, and include six highlights below.